S&P 500 7,741 +5.80% Nasdaq 26,453 +8.22% Dow Jones 54,481 +5.59% FTSE 100 10,888 -0.18% DAX 26,126 +2.62% Nikkei 225 66,300 +7.17% Hang Seng 25,916 +0.42% WTI Crude 75.27 -11.10% Gold 4,322 +6.75% US 10-Year Treasury Yield 4.615 -1.03% S&P 500 7,741 +5.80% Nasdaq 26,453 +8.22% Dow Jones 54,481 +5.59% FTSE 100 10,888 -0.18% DAX 26,126 +2.62% Nikkei 225 66,300 +7.17% Hang Seng 25,916 +0.42% WTI Crude 75.27 -11.10% Gold 4,322 +6.75% US 10-Year Treasury Yield 4.615 -1.03%

LATEST

Hormuz Crisis Is Rewriting the Global LPG Trade●Why AT&T, Verizon and T-Mobile shares are down after SpaceX’s earnings●Pentagon drafts new nuclear strategy weighing tactical weapons against Russia, China●AI lows are in — here’s how to position before the next rally●Want income without leaving the market? Here’s the strategy●Marex invests in Digital Prime to expand institutional crypto lending●Microsoft AI exec tells developers to default to OpenAI's top model as part of efficiency push●Feds Say an NFT Founder Raised $10 Million Only to Blow It All on Gambling, Trading, and a DJ Hobby●Hormuz Crisis Is Rewriting the Global LPG Trade●Why AT&T, Verizon and T-Mobile shares are down after SpaceX’s earnings●Pentagon drafts new nuclear strategy weighing tactical weapons against Russia, China●AI lows are in — here’s how to position before the next rally●Want income without leaving the market? Here’s the strategy●Marex invests in Digital Prime to expand institutional crypto lending●Microsoft AI exec tells developers to default to OpenAI's top model as part of efficiency push●Feds Say an NFT Founder Raised $10 Million Only to Blow It All on Gambling, Trading, and a DJ Hobby●

Front Page

Soriot should explain the curious case of AstraZeneca’s non-deal

Business | The Guardian · 1h ago · 🇺🇸 United States

Soriot should explain the curious case of AstraZeneca’s non-deal

AstraZeneca’s rumoured takeover of Bristol Myers Squibb already looked weird, and was met with a lack of enthusiasm by shareholders Hold the heartburn pills. It seems AstraZeneca is no longer contemplating a takeover of US rival Bristol Myers Squibb (BMS) to create a $400bn (£300bn) pharmaceutical colossus . On Monday, the UK firm’s shares plunged 9% on the FT’s report of preliminary talks . On Wednesday, Reuters said there are no ongoing discussions. Cue a mini-relief rally in AZ’s share price. Neither company has seen fit to tell its shareholders what was happening, so it’s impossible to kno

Read the full story at Business | The Guardian →

More Front Page

Flutter shares plummet on earnings miss and another key leadership change

Business News · 52m ago

Trump's 'Liberation Day' tariff refunds hit $100bn

BBC News · 1h ago

3 Dividend Stocks Ready to Pay You – If You Buy Them This Week

Yahoo Finance · 1h ago

SpaceX's Bitcoin holding loses $540 million in six months

Yahoo Finance · 1h ago